Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

HEENA SHAH PATEL

Allopathic & Osteopathic Physicians Allergy & Immunology

NPI
1881916864
CMS profile
1312872
Location
UPLAND, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$39,679.64

119 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 3 of 3; records 101–119 of 119 matching records. This page contains 19 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

HEENA SHAH PATEL

NPI 1881916864 · CMS profile ID 1312872

Allopathic & Osteopathic Physicians / Allergy & Immunology

UPLAND, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–119 of 119 matching records. This page contains 19 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1881916864?year=2019&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
HEENA SHAH PATEL, NPI 1881916864, CMS profile ID 1312872. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–119 of 119 matching records. This page contains 19 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1881916864?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). HEENA SHAH PATEL, NPI 1881916864, CMS profile ID 1312872. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–119 of 119 matching records. This page contains 19 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1881916864?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
HEENA SHAH PATEL, NPI 1881916864, CMS profile ID 1312872, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–119 of 119 matching records. This page contains 19 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1881916864?year=2019&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

119 matching records · $39,679.64 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 119 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–119 of 119.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GENZYME CORPORATION $23.0002/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693935723 CMS
GlaxoSmithKline, LLC. $800.4002/20/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670360447 CMS
GlaxoSmithKline, LLC. $119.1502/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670691221 CMS
AstraZeneca Pharmaceuticals LP $21.8802/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685139795 CMS
AstraZeneca Pharmaceuticals LP $45.4002/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685749501 CMS
GlaxoSmithKline, LLC. $2,400.0002/14/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671495587 CMS
OptiNose US, Inc. $9.2602/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684240197 CMS
GlaxoSmithKline, LLC. $10.2802/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670362961 CMS
GlaxoSmithKline, LLC. $0.9902/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671522433 CMS
AstraZeneca Pharmaceuticals LP $16.0302/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685567999 CMS
Sunovion Pharmaceuticals Inc. $85.6001/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694944299 CMS
OptiNose US, Inc. $4.3601/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684240193 CMS
Regeneron Healthcare Solutions, Inc. $64.1101/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673474045 CMS
Sunovion Pharmaceuticals Inc. $4.4701/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694944291 CMS
GENZYME CORPORATION $96.2401/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693921169 CMS
Sunovion Pharmaceuticals Inc. $4.8301/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694944295 CMS
AstraZeneca Pharmaceuticals LP $15.6501/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685481847 CMS
GENZYME CORPORATION $9.7801/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693903367 CMS
CSL Behring $12.9801/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683854531 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $39,679.64 119
PY2020 $16,258.17 57
PY2021 $32,840.24 151
PY2022 $30,065.95 154
PY2023 $140,239.20 305
PY2024 $98,869.79 215
PY2025 $70,029.75 232

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $80,050.27 41
PY2024 Principal investigator $27,508.08 31
PY2023 Principal investigator $37,052.88 13
PY2022 Principal investigator $7,926.28 3
PY2021 Principal investigator $9,532.77 7
PY2020 Principal investigator $36,294.11 10
PY2019 Principal investigator $67,586.21 8

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

41 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 GENZYME CORPORATION $593.00 12/22/2025 Non-covered Recipient Entity
Integrated Research Of Inland Inc
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226125890
Principal investigator 1 GENZYME CORPORATION $2,376.00 12/22/2025 Non-covered Recipient Entity
Integrated Research Of Inland Inc
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226125894
Principal investigator 1 GENZYME CORPORATION $3,922.00 12/15/2025 Non-covered Recipient Entity
Integrated Research Of Inland Inc
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226125881
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $182.25 11/17/2025 Non-covered Recipient Entity
INTEGRATED RESEARCH OF INLAND INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184261555
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $90.45 11/17/2025 Non-covered Recipient Entity
INTEGRATED RESEARCH OF INLAND INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184261557
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $113.40 11/17/2025 Non-covered Recipient Entity
INTEGRATED RESEARCH OF INLAND INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184261559
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $79.65 11/17/2025 Non-covered Recipient Entity
INTEGRATED RESEARCH OF INLAND INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184261561
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $706.05 11/17/2025 Non-covered Recipient Entity
INTEGRATED RESEARCH OF INLAND INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184261563
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $97.20 11/17/2025 Non-covered Recipient Entity
INTEGRATED RESEARCH OF INLAND INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184261565
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $148.50 11/17/2025 Non-covered Recipient Entity
INTEGRATED RESEARCH OF INLAND INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184261567
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $85.05 11/17/2025 Non-covered Recipient Entity
INTEGRATED RESEARCH OF INLAND INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184261569
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $39.15 11/17/2025 Non-covered Recipient Entity
INTEGRATED RESEARCH OF INLAND INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184261571
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $391.50 11/17/2025 Non-covered Recipient Entity
INTEGRATED RESEARCH OF INLAND INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184261573
Principal investigator 1 GENZYME CORPORATION $55.00 11/04/2025 Non-covered Recipient Entity
Integrated Research Of Inland Inc
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226125872
Principal investigator 1 GENZYME CORPORATION $2,376.00 09/22/2025 Non-covered Recipient Entity
Integrated Research Of Inland Inc
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226125857
Principal investigator 1 GENZYME CORPORATION $52.50 07/21/2025 Non-covered Recipient Entity
Integrated Research Of Inland Inc
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226125829
Principal investigator 1 GENZYME CORPORATION $2,505.00 07/14/2025 Non-covered Recipient Entity
Integrated Research Of Inland Inc
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226125845
Principal investigator 1 GENZYME CORPORATION $2,376.00 06/23/2025 Non-covered Recipient Entity
Integrated Research Of Inland Inc
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226125821
Principal investigator 1 GENZYME CORPORATION $2,620.00 06/09/2025 Non-covered Recipient Entity
Integrated Research Of Inland Inc
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226125796
Principal investigator 1 GENZYME CORPORATION $991.00 05/27/2025 Non-covered Recipient Entity
Integrated Research Of Inland Inc
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226125780
Principal investigator 1 AstraZeneca UK Limited $33,725.12 05/21/2025 Non-covered Recipient Entity
INTEGRATED RESEARCH OF INLAND INC
a randomized,double blind,multicenter,parallel group,phase IIIb 52 week study evaluating the efficacy and safety of PT027 compared with PT007 administered as needed in participants 12 to under 18 years of age with asthma ACADIA No dispute reported 06/30/2026 1185553541
Principal investigator 1 GENZYME CORPORATION $3,971.00 05/12/2025 Non-covered Recipient Entity
Integrated Research Of Inland Inc
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226125792
Principal investigator 1 GENZYME CORPORATION $1,798.00 03/24/2025 Non-covered Recipient Entity
Integrated Research Of Inland Inc
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226125769
Principal investigator 1 GENZYME CORPORATION $3,971.00 02/24/2025 Non-covered Recipient Entity
Integrated Research Of Inland Inc
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226125760
Principal investigator 1 GENZYME CORPORATION $457.00 02/10/2025 Non-covered Recipient Entity
Integrated Research Of Inland Inc
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226125747
Principal investigator 1 GENZYME CORPORATION $200.00 02/10/2025 Non-covered Recipient Entity
Integrated Research Of Inland Inc
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226125751
Principal investigator 1 GENZYME CORPORATION $2,376.00 02/10/2025 Non-covered Recipient Entity
Integrated Research Of Inland Inc
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226125754
Principal investigator 1 Incyte Corporation $27.27 01/09/2025 Non-covered Recipient Entity
INTEGRATED RESEARCH OF INLAND, INC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240539620
Principal investigator 1 Incyte Corporation $9.18 01/09/2025 Non-covered Recipient Entity
INTEGRATED RESEARCH OF INLAND, INC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240539625
Principal investigator 1 Incyte Corporation $6.60 01/09/2025 Non-covered Recipient Entity
INTEGRATED RESEARCH OF INLAND, INC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240539629
Principal investigator 1 Incyte Corporation $4.66 01/09/2025 Non-covered Recipient Entity
INTEGRATED RESEARCH OF INLAND, INC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240539633
Principal investigator 1 Incyte Corporation $1.20 01/09/2025 Non-covered Recipient Entity
INTEGRATED RESEARCH OF INLAND, INC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240539636
Principal investigator 1 Incyte Corporation $4.32 01/09/2025 Non-covered Recipient Entity
INTEGRATED RESEARCH OF INLAND, INC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240539640
Principal investigator 1 Incyte Corporation $60.58 01/09/2025 Non-covered Recipient Entity
INTEGRATED RESEARCH OF INLAND, INC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240539644
Principal investigator 1 Incyte Corporation $205.26 01/09/2025 Non-covered Recipient Entity
INTEGRATED RESEARCH OF INLAND, INC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240539648
Principal investigator 1 Incyte Corporation $52.48 01/09/2025 Non-covered Recipient Entity
INTEGRATED RESEARCH OF INLAND, INC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240539653
Principal investigator 1 Incyte Corporation $5.40 01/09/2025 Non-covered Recipient Entity
INTEGRATED RESEARCH OF INLAND, INC
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants with Inadequately Controlled Moderate-to-Severe Asthma No dispute reported 06/30/2026 1240539657
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,071.00 01/08/2025 Non-covered Recipient Entity
INTEGRATED RESEARCH OF INLAND INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184147303
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,500.00 01/08/2025 Non-covered Recipient Entity
INTEGRATED RESEARCH OF INLAND INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184147305
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,789.00 01/08/2025 Non-covered Recipient Entity
INTEGRATED RESEARCH OF INLAND INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184147307
Principal investigator 1 GENZYME CORPORATION $15.50 01/06/2025 Non-covered Recipient Entity
Integrated Research Of Inland Inc
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226125776